NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype
Open Access
- 17 May 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Abstract
Patients with peripheral artery disease (PAD) are at high risk of excess mortality despite major improvements in multimodal pharmacotherapy for cardiovascular disease. However, little is known about co-prevalences and implications for the combination of heart failure (HF) and PAD. Thus, NT-proBNP as a suggested surrogate for HF was evaluated in symptomatic PAD regarding long-term mortality. After approval by the institutional ethics committee a total of 1028 patients with PAD, both with intermittent claudication or critical limb ischemia were included after admission for endovascular repair and were followed up for a median of 4.6 years. Survival information was obtained from central death database queries. During the observation period a total of 336 patients died (calculated annual death rate of 7.1%). NT-proBNP (per one standard deviation increase) was highly associated with outcome in the general cohort in crude (HR 1.86, 95%CI 1.73–2.01) and multivariable-adjusted Cox-regression analyses with all-cause mortality (HR 1.71, 95%CI 1.56–1.89) and CV mortality (HR 1.86, 95% CI 1.55–2.15). Similar HR’s were found in patients with previously documented HF (HR 1.90, 95% CI 1.54–2.38) and without (HR 1.88, 95%CI 1.72–2.05). NT-proBNP levels were independently associated with below-the-knee lesions or multisite target lesions (OR 1.14, 95% CI 1.01–1.30). Our data indicate that increasing NT-proBNP levels are independently associated with long-term mortality in symptomatic PAD patients irrespective of a previously documented HF diagnosis. HF might thus be highly underreported in PAD, especially in patients with the need for below-the-knee revascularization.Keywords
This publication has 45 references indexed in Scilit:
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up StudyMayo Clinic Proceedings, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) RegistryAtherosclerosis, 2009
- Amino-Terminal Pro–B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease StudyClinical Chemistry, 2009
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)European Journal of Vascular and Endovascular Surgery, 2007
- NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patientsEuropean Heart Journal, 2005
- Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overloadAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) studyThe American Journal of Cardiology, 2005
- Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and DeathNew England Journal of Medicine, 2004